SEC Form 4 · accession 0001213900-26-097742
Actinium Pharmaceuticals, Inc. · ATNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
June Sherie Almenoff
Director
Period of report
Sep 2, 2026
Accepted (ET)
Sep 4, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001388320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 2, 2026 | A | 18,000 | $0.00 | A | 18,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.00 | Sep 2, 2026 | A | 27,000 | A | — | Sep 2, 2036 | Common Stock | 27,000 | 27,000 | D |
Explanation of responses
- F1Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant.
- F2The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant.